Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Leigh

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
Molecular Neurodegeneration|August 10, 2018
Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseasesJason A Chen, Zhongbo Chen, Hyejung Won, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 7, 2019
Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsyZhongbo Chen, Jason A Chen, Aleksey Shatunov, et al.
International Journal of Molecular Sciences|December 11, 2022
Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear PalsyFabio A Simoes, Greig Joilin, Oliver Peters, et al.
Science (New York, N.Y.)|March 3, 2009
Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6Caroline Vance, Boris Rogelj, Tibor Hortobágyi, et al.
Neurology|October 6, 2017
Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trialsRuben P A van Eijk, Ashley R Jones, William Sproviero, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 20, 2024
Evaluation of Cerebrospinal Fluid α-Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal SyndromeDavid P Vaughan, Riona Fumi, Marte Theilmann Jensen, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
The Lancet. Neurology|October 11, 2014
Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling studyAmmar Al-Chalabi, Andrea Calvo, Adriano Chio, et al.
Nature Genetics|July 9, 2003
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic deathDiether Lambrechts, Erik Storkebaum, Masafumi Morimoto, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 16, 2026
Biomarkers of Leucine-Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear PalsyLouise-Kristine Nielsen, Joshua L I Frost, David P Vaughan, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Molecular Neurodegeneration|August 10, 2018
Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseasesJason A Chen, Zhongbo Chen, Hyejung Won, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 7, 2019
Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsyZhongbo Chen, Jason A Chen, Aleksey Shatunov, et al.
International Journal of Molecular Sciences|December 11, 2022
Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear PalsyFabio A Simoes, Greig Joilin, Oliver Peters, et al.
Science (New York, N.Y.)|March 3, 2009
Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6Caroline Vance, Boris Rogelj, Tibor Hortobágyi, et al.
Neurology|October 6, 2017
Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trialsRuben P A van Eijk, Ashley R Jones, William Sproviero, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 20, 2024
Evaluation of Cerebrospinal Fluid α-Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal SyndromeDavid P Vaughan, Riona Fumi, Marte Theilmann Jensen, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
The Lancet. Neurology|October 11, 2014
Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling studyAmmar Al-Chalabi, Andrea Calvo, Adriano Chio, et al.
Nature Genetics|July 9, 2003
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic deathDiether Lambrechts, Erik Storkebaum, Masafumi Morimoto, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 16, 2026
Biomarkers of Leucine-Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear PalsyLouise-Kristine Nielsen, Joshua L I Frost, David P Vaughan, et al.
Pageof 15